documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
44 rows where docket_id = "FDA-1994-P-0028" and posted_year = 2017 sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_date, posted_month, comment_start_date, posted_date (date), comment_start_date (date), last_modified (date)
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-1994-P-0028-0047 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Tab G: Letter from Geneva Pharmaceuticals to FDA CDER re: Petition for Stay of Action from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-12-29T05:00:00Z | 2017 | 12 | 2017-12-29T16:45:07Z | 0 | 0 | 09000064804fd363 | |||
| FDA-1994-P-0028-0046 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Tab G: Letter from Geneva Pharmaceuticals to FDA CDER re Correction from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo) | Supporting & Related Material | Background Material | 2017-12-29T05:00:00Z | 2017 | 12 | 2017-12-29T16:44:36Z | 0 | 0 | 09000064804fd353 | |||
| FDA-1994-P-0028-0045 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Citizen Petition Denial Response Letter from FDA ORA to Mckenna & Cuneo | Other | Denial of Petition | 2017-10-05T04:00:00Z | 2017 | 10 | 2017-10-05T04:00:00Z | 2017-10-05T13:53:52Z | 0 | 0 | 09000064804fd37c | ||
| FDA-1994-P-0028-0021 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Exhibit 1: Letter from FDA CDER re Correction from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T15:21:40Z | 0 | 0 | 09000064804fd355 | |||
| FDA-1994-P-0028-0035 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Tab F: U. S. District Court for the District of Colorado Marion Merrell Dow, Inc v. Geneva Pharmaceuticals, Inc. re: Petition for Stay of Action from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T18:57:17Z | 0 | 0 | 09000064804fd36c | |||
| FDA-1994-P-0028-0028 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Attachment 1: Citizen Petition from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) re: Petition for Stay of Action from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T18:31:00Z | 0 | 0 | 09000064804fd36a | |||
| FDA-1994-P-0028-0038 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Exhibit 2: Letter from FDA CDER to American Therapeutics, Inc. re: Petition for Stay of Action from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T19:18:01Z | 0 | 0 | 09000064804fd360 | |||
| FDA-1994-P-0028-0023 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Exhibit 3: U. S. District Court for District of New Jersey Barr Lab vs Otis Bowen et al, re Correction from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T16:07:24Z | 0 | 0 | 09000064804fd357 | |||
| FDA-1994-P-0028-0032 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Tab C: FDA Approved Drug Products with Therapeutic Equivalence Evaluations (13th Ed and 6th Ed) re: Petition for Stay of Action from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T18:45:33Z | 0 | 0 | 09000064804fd366 | |||
| FDA-1994-P-0028-0031 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Tab B: FDA Approved Drug Products with Therapeutic Equivalence Evaluations 11th Edition re: Petition for Stay of Action from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T18:41:44Z | 0 | 0 | 09000064804fd367 | |||
| FDA-1994-P-0028-0029 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Attachment 2: U. S. District Court for District of Columbia Geneva Pharmaceuticals Inc vs. USA re: Petition for Stay of Action from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T18:35:38Z | 0 | 0 | 09000064804fd369 | |||
| FDA-1994-P-0028-0022 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Exhibit 2: Letter from FDA CDER to American Therapeutics, Inc. re Correction from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T15:23:40Z | 0 | 0 | 09000064804fd356 | |||
| FDA-1994-P-0028-0027 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Petition for Stay of Action from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Other | Petition for Reconsideration | 2017-10-04T04:00:00Z | 2017 | 10 | 1994-07-12T04:00:00Z | 2017-10-04T18:25:17Z | 0 | 0 | 09000064804fd36b | ||
| FDA-1994-P-0028-0033 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Tab D: Letter From Geneva Pharmaceuticals, Inc. To FDA CDER re: Petition for Stay of Action from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T18:48:35Z | 0 | 0 | 09000064804fd365 | |||
| FDA-1994-P-0028-0042 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Attachment 4 U. S. District Court for District Columbia Geneva Pharmaceuticals Inc, v USA re: Petition for Stay of Action from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T19:38:48Z | 0 | 0 | 09000064804fd35b | |||
| FDA-1994-P-0028-0024 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Exhibit 4: Letter from FDA CDER to Vitarine Pharmaceuticals, Inc. re Correction from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T15:28:40Z | 0 | 0 | 09000064804fd358 | |||
| FDA-1994-P-0028-0015 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Tab C: FDA Approved Drug Products with Therapeutic Equivalence Evaluations (13th Ed and 6th Ed) re Correction from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T15:09:10Z | 0 | 0 | 09000064804fd34a | |||
| FDA-1994-P-0028-0037 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Exhibit 1: Letter from FDA CDER re: Petition for Stay of Action from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T19:15:48Z | 0 | 0 | 09000064804fd361 | |||
| FDA-1994-P-0028-0040 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Exhibit 4: Letter from FDA CDER to Vitarine Pharmaceuticals, Inc. re: Petition for Stay of Action from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T19:28:48Z | 0 | 0 | 09000064804fd35d | |||
| FDA-1994-P-0028-0039 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Exhibit 3: U. S. District Court District of New Jersey Barr Lab v. Otis Bowen, et. al., re: Petition for Stay of Action from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T19:22:09Z | 0 | 0 | 09000064804fd35f | |||
| FDA-1994-P-0028-0036 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Tab H: Letter from FDA OGC to McKenna & Cuneo re: Petition for Stay of Action from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T19:05:14Z | 0 | 0 | 09000064804fd362 | |||
| FDA-1994-P-0028-0012 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Attachment 1: U. S. District Court for District of Columbia Geneva Pharmaceuticals Inc. v. USA re Correction from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T16:03:18Z | 0 | 0 | 09000064804fd342 | |||
| FDA-1994-P-0028-0025 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Attachment 2 U. S. District Court for District of Columbia Geneva Pharmaceutical, Inc. vs USA re Correction from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T15:52:05Z | 0 | 0 | 0900006482b9ba01 | |||
| FDA-1994-P-0028-0030 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Tab A: Letter from Geneva Pharmaceuticals to FDA CDER re: Petition for Stay of Action from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T18:38:39Z | 0 | 0 | 09000064804fd368 | |||
| FDA-1994-P-0028-0017 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Tab E: Letter from Geneva Pharmaceuticals, Inc. to Marion Merrell Dow re Correction from Geneva Pharmaceuticals, Inc. ( McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T15:08:55Z | 0 | 0 | 09000064804fd34f | |||
| FDA-1994-P-0028-0018 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Tab 2: U. S. District Court D.C. Geneva Pharmaceuticals vs. USA re Correction from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T15:47:18Z | 0 | 0 | 09000064804fd351 | |||
| FDA-1994-P-0028-0034 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Tab E: Letter from Geneva Pharmaceuticals to Marion Merrell Dow re: Petition for Stay of Action from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T18:52:25Z | 0 | 0 | 09000064804fd364 | |||
| FDA-1994-P-0028-0013 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Tab A: Letter from Geneva Pharmaceuticals, Inc. to FDA CDER re Correction from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T15:09:27Z | 0 | 0 | 09000064804fd345 | |||
| FDA-1994-P-0028-0026 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Attachment 3: U. S. District Court for District of Columbia Geneva Pharmaceuticals, Inc. vs. USA re Correction from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T15:55:36Z | 0 | 0 | 09000064804fd35a | |||
| FDA-1994-P-0028-0014 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Tab B: FDA Approved Drug Products with Therapeutic Equivalence (11th Edition) re Correction from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T15:09:18Z | 0 | 0 | 09000064804fd347 | |||
| FDA-1994-P-0028-0016 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Tab D: Letter from Geneva Pharmaceuticals, Inc. to FDA CDER re Correction from Geneva Pharmaceuticals, Inc. ( McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T15:09:02Z | 0 | 0 | 09000064804fd34c | |||
| FDA-1994-P-0028-0019 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Tab F: U. S. District Court for District of Columbia Marion Merrell Dow, Inc. vs Geneva Pharmaceuticals, Inc. re Correction from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T16:13:00Z | 0 | 0 | 09000064804fd352 | |||
| FDA-1994-P-0028-0041 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Attachment 3 U. S. District Court for District of Columbia Geneva Pharmaceuticals Inc, V. United States of America re : Petition for Stay of Action from Geneva Pharmaceuticals, Inc. (McKenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T19:34:20Z | 0 | 0 | 09000064804fd35c | |||
| FDA-1994-P-0028-0020 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Tab H: Letter from FDA OCG to McKenna & Cuneo re Correction from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo) | Supporting & Related Material | Background Material | 2017-10-04T04:00:00Z | 2017 | 10 | 2017-10-04T15:18:40Z | 0 | 0 | 09000064804fd354 | |||
| FDA-1994-P-0028-0007 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Exhibit 4: Letter from FDA CDER to Vitarine Pharmaceuticals, Inc. re Citizen Petition from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo) | Supporting & Related Material | Background Material | 2017-09-29T04:00:00Z | 2017 | 9 | 2017-10-04T16:09:13Z | 0 | 0 | 0900006482a1e114 | |||
| FDA-1994-P-0028-0010 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Acknowledgment Letter from FDA DDM to McKenna & Cuneo | Other | Acknowledgement Letter/Receipt | 2017-09-29T04:00:00Z | 2017 | 9 | 2017-09-29T04:00:00Z | 2017-09-29T18:29:46Z | 0 | 0 | 09000064804fd37e | ||
| FDA-1994-P-0028-0011 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Correction from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo) | Other | Correction(s) | 2017-09-29T04:00:00Z | 2017 | 9 | 1994-07-12T04:00:00Z | 2017-10-04T14:39:08Z | 0 | 0 | 09000064804fd359 | ||
| FDA-1994-P-0028-0005 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Exhibit 2: Letter from FDA CDER to American Therapeutics, Inc. re Citizen Petition from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo) | Supporting & Related Material | Background Material | 2017-09-29T04:00:00Z | 2017 | 9 | 2017-10-04T16:06:35Z | 0 | 0 | 0900006482a1d907 | |||
| FDA-1994-P-0028-0004 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Exhibit 1: Letter from FDA CDER re Citizen Petition from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo) | Supporting & Related Material | Background Material | 2017-09-29T04:00:00Z | 2017 | 9 | 2017-10-04T16:05:39Z | 0 | 0 | 0900006482a1cef1 | |||
| FDA-1994-P-0028-0008 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Attachment 2 U. S. District Court for District of Columbia Geneva Pharmaceutical, Inc. vs USA re Citizen Petition from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo) | Supporting & Related Material | Background Material | 2017-09-29T04:00:00Z | 2017 | 9 | 2017-09-29T18:22:27Z | 0 | 0 | 0900006482a1def0 | |||
| FDA-1994-P-0028-0009 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Attachment 3 U. S. District Court for District of Columbia Geneva Pharmaceutical, Inc. vs USA re Citizen Petition from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo) | Supporting & Related Material | Background Material | 2017-09-29T04:00:00Z | 2017 | 9 | 2017-09-29T18:27:11Z | 0 | 0 | 0900006482a1e043 | |||
| FDA-1994-P-0028-0003 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Attachment 1 U. S. District Court for District of Columbia Geneva Pharmaceutical, Inc. vs USA re Citizen Petition from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo) | Supporting & Related Material | Background Material | 2017-09-29T04:00:00Z | 2017 | 9 | 2017-09-29T18:00:13Z | 0 | 0 | 0900006482a1c493 | |||
| FDA-1994-P-0028-0006 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Exhibit 3: U. S. District Court of New Jersey Barr Lab Inc. v. Otis Bowen et al., re Citizen Petition from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo) | Supporting & Related Material | Background Material | 2017-09-29T04:00:00Z | 2017 | 9 | 2017-10-04T15:46:14Z | 0 | 0 | 0900006482a1d6d2 | |||
| FDA-1994-P-0028-0002 | FDA | Acknowledge Geneva's Right to 180 days of Market Exclusivity Terfenadine-CLOSED FDA-1994-P-0028 | Citizen Petition from Geneva Pharmaceuticals, Inc. (Mckenna & Cuneo) | Other | Citizen Petition | 2017-09-22T04:00:00Z | 2017 | 9 | 1994-07-08T04:00:00Z | 2017-10-06T01:04:22Z | 0 | 0 | 09000064804fd340 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);